Navigation Links
Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
Date:10/2/2008

SYDNEY, Australia, Oct. 3 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS, NASDAQ: PXSL) has announced that researchers will present 12 abstracts from its respiratory disease program at the 2008 European Respiratory Society Congress (ERS) being held in Berlin from the 4th to the 8th October. The ERS brings together many of the world's top respiratory researchers and clinicians to hear latest advances in clinical diagnosis and treatment.

A comprehensive program of research will be presented in ERS symposiums and poster sessions relating to the lung challenge product, Aridol, and the mucus clearing agent, Bronchitol.

In a poster session Professor Di Bilton, Consultant Physician and Honorary Senior Lecturer at the Department of Respiratory Medicine, The Royal Brompton Hospital, London, UK, will detail results of a successful randomized, placebo- controlled trial of inhaled mannitol (Bronchitol) in patients with bronchiectasis.

Other key ERS program events from the Pharmaxis respiratory disease program include:

-- The use of inhaled mannitol (Aridol) for assessing airway disease

-- Direct versus indirect airway challenges

-- Using a dry powder of mannitol (Aridol) versus methacholine as

challenge for routine practice

-- Inhaled mannitol (Bronchitol) as treatment for children with cystic

fibrosis

-- Implications for everyday practice

-- Infectious lung diseases including tuberculosis

-- A randomized, placebo-controlled trial of inhaled

mannitol(Bronchitol) in patients with bronchiectasis

-- Cough and airway hyperresponsiveness

-- A comparison of inhaled mannitol (Aridol), methacholine

provocation and eucapnic voluntary hyperventilation as diagnostic

tests for exercised-induced bronchoconstriction in cross country

skiers

-- Assessment of inflammation, hyperresponsiveness and response to

exercise in asthmatic children

-- Mannitol dry powder challenge (Aridol) in comparison with exercise

testing and methacholine challenge test in children

-- Responsiveness to mannitol (Aridol) and exercise challenge in

children with asthma

-- Association between mannitol dry powder challenge (Aridol) test

results and fractional exhaled nitric oxide in children

-- Exercise-induced asthma, acute severe asthma and allergic rhinitis in

children

-- Change of exercise challenge tests and mannitol challenge test

(Aridol) during optimized asthma treatment in adolescents with

exercise induced asthma

-- Investigation, inspiration, ventilation, dedication: the essence of

physiological measurement

-- The perception of breathlessness during bronchoconstriction induced

by mannitol (Aridol) in COPD

-- Phenotyping of asthma and COPD

-- Airway hyperresponsiveness to mannitol (Aridol) and exhaled NO are

related to inflammatory subtypes in asthma.

ERS is Europe's biggest annual scientific gathering in respiratory medicine, with more than 17,000 participants each year. It aims to provide a platform for important improvements in the treatment of lung diseases. Full details of ERS may be viewed on the ERS website at http://dev.ersnet.org/415-general-information.htm

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Alan Robertson - Chief Executive Officer

Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

RELEASED THROUGH:

Australia:

Felicity Moffatt, phone +61 418 677 701 or email

felicity.moffatt@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group, phone +1 646 378 2915 or email

blewis@troutgroup.com

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.


'/>"/>
SOURCE Pharmaxis
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Pharmaxis Board Appointment
2. Pharmaxis Aridol Authorised for Sale in Germany
3. Pharmaxis First Steps into China
4. Pharmaxis to Apply to Market Bronchitol in Australia
5. Pharmaxis Investor Conference Call
6. Pharmaxis Aridol Gains First Asian Approval
7. Pharmaxis Appoints Portuguese Distributor for Aridol
8. Pharmaxis Closes Share Purchase Plan
9. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. Halozyme Therapeutics to Host Research Day for Investors and Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey and collaborator Just Biotherapeutics, ... solution, LabKey Biologics . Built in collaboration with Just and designed with ... provides drug research teams tools for biological entity registration, assay data integration, and ...
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... ROCKVILLE, Md. , March 27, 2017 /PRNewswire/ ... $108.5 billion for 2016, according to a new ... patients, medical lab testing is performed to evaluate ... determine individual therapy, among other reasons.  The healthcare ... Services Market , provides an overview of ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Who risk ... lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:2/28/2017)... --  Acuant , a leading provider of data capture ... new and core technologies building upon the acquisition of ... desktop Acuant FRM TM facial recognition and match ... manual review of identity documents by accredited professionals. ... most accurate capture software to streamline workflows by securely ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
Breaking Biology News(10 mins):